Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older. Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, et al. Vaccine 2025;61:127433.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older. Vaccine 2025;61:127433.
PMID: 40609266